These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 1849076

  • 21. Structure and functions of gp 140, the C3d/EBV receptor (CR2) of human B lymphocytes.
    Frade R.
    Mol Immunol; 1986 Nov; 23(11):1249-53. PubMed ID: 2950318
    [Abstract] [Full Text] [Related]

  • 22. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.
    Iida K, Nadler L, Nussenzweig V.
    J Exp Med; 1983 Oct 01; 158(4):1021-33. PubMed ID: 6225820
    [Abstract] [Full Text] [Related]

  • 23. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).
    Ahearn JM, Fearon DT.
    Adv Immunol; 1989 Oct 01; 46():183-219. PubMed ID: 2551147
    [No Abstract] [Full Text] [Related]

  • 24. Nuclear localization of the Epstein-Barr virus/C3d receptor (CR2) in the human Burkitt B lymphoma cell, Raji.
    Gauffre A, Viron A, Barel M, Hermann J, Puvion E, Frade R.
    Mol Immunol; 1992 Sep 01; 29(9):1113-20. PubMed ID: 1323059
    [Abstract] [Full Text] [Related]

  • 25. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
    Lambris JD, Ganu VS, Hirani S, Müller-Eberhard HJ.
    Proc Natl Acad Sci U S A; 1985 Jun 01; 82(12):4235-9. PubMed ID: 2408276
    [Abstract] [Full Text] [Related]

  • 26. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2009 Apr 03; 284(14):9513-20. PubMed ID: 19164292
    [Abstract] [Full Text] [Related]

  • 27. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.
    Nemerow GR, Siaw MF, Cooper NR.
    J Virol; 1986 May 03; 58(2):709-12. PubMed ID: 2422399
    [Abstract] [Full Text] [Related]

  • 28. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
    Nemerow GR, Mullen JJ, Dickson PW, Cooper NR.
    J Virol; 1990 Mar 03; 64(3):1348-52. PubMed ID: 2154612
    [Abstract] [Full Text] [Related]

  • 29. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
    Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM.
    J Immunol; 2006 Jul 01; 177(1):383-94. PubMed ID: 16785534
    [Abstract] [Full Text] [Related]

  • 30. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
    Nemerow GR, Wolfert R, McNaughton ME, Cooper NR.
    J Virol; 1985 Aug 01; 55(2):347-51. PubMed ID: 2410629
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).
    Fingeroth JD, Clabby ML, Strominger JD.
    J Virol; 1988 Apr 01; 62(4):1442-7. PubMed ID: 2831405
    [Abstract] [Full Text] [Related]

  • 34. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor.
    Fujisaku A, Harley JB, Frank MB, Gruner BA, Frazier B, Holers VM.
    J Biol Chem; 1989 Feb 05; 264(4):2118-25. PubMed ID: 2563370
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
    Nemerow GR, Houghten RA, Moore MD, Cooper NR.
    Cell; 1989 Feb 10; 56(3):369-77. PubMed ID: 2464439
    [Abstract] [Full Text] [Related]

  • 37. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.
    J Immunol; 2001 Aug 01; 167(3):1490-9. PubMed ID: 11466369
    [Abstract] [Full Text] [Related]

  • 38. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
    Martin DR, Yuryev A, Kalli KR, Fearon DT, Ahearn JM.
    J Exp Med; 1991 Dec 01; 174(6):1299-311. PubMed ID: 1660522
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CR2 complement receptor.
    Cooper NR, Bradt BM, Rhim JS, Nemerow GR.
    J Invest Dermatol; 1990 Jun 01; 94(6 Suppl):112S-117S. PubMed ID: 2161885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.